-
1Academic Journal
Authors: I. A. Strokov, V. V. Oganov, И. А. Строков, В. В. Оганов
Contributors: This article has been supported by Kanonfarma prodakshn, Статья спонсируется компанией ЗАО «Канонфарма продакшн»
Source: Neurology, Neuropsychiatry, Psychosomatics; Vol 13, No 3 (2021); 99-106 ; Неврология, нейропсихиатрия, психосоматика; Vol 13, No 3 (2021); 99-106 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2021-3
Subject Terms: болезнь-модифицирующая терапия, diabetic polyneuropathy, evaluation, pathogenetic therapy, alpha-lipoic acid, symptom-modifying treatment, disease-modifying treatment, диабетическая полиневропатия, диагностика, патогенетическая терапия, альфа-липоевая кислота, симптом-модифицирующая терапия
File Description: application/pdf
Relation: https://nnp.ima-press.net/nnp/article/view/1584/1262; Wang L, Gao P, Zhang M, et al. Prevalence and ethnic pattern of diabetes and prediabetes in China in 2013. JAMA. 2017 Jun 27;317(24):2515-23. doi:10.1001/jama.2017.7596; International Diabetes Federation Atlas. 8th ed. 2017. Available from: https://diabetesatlas.org/upload/resources/previous/files/8/IDF_DA_8e-EN-final.pdf; Котов СВ, Калинин АП, Рудакова ИГ. Диабетическая нейропатия. Москва: МИА; 2011. 438 с.; Tesfaye S, Boulton AJM, Dyck PJ, et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010 Oct;33(10):2285-93. doi:10.2337/dc10-1303; Babizhayev MA, Nosikov VV, Strokov IA, et al. The role of oxidative stress in diabetic neuropathy: generation of free radical species in the glycation reaction and gene polymorphisms encoding antioxidant enzymes to genetic susceptibility to diabetic neuropathy in population of type I diabetic patients. Cell Biochem Biophys. 2015 Apr;71(3):1425-43. doi:10.1007/s12013-014-0365-y; Strokov IA, Bursa TR, Drepa OI, et al. Predisposing genetic factors for diabetic polyneuropathy in patients with type 1 diabetes: a population-based case-control study. Acta Diabetol. 2003 Dec;40 Suppl 2:S375-9. doi:10.1007/s00592-003-0123-x; Albers JW, Pop-Busui R. Diabetic neuropathy: mechanisms, emerging treatments, and subtypes. Curr Neurol Neurosci Rep. 2014 Aug;14(8):473. doi:10.1007/s11910-014-0473-5; Строков ИА, Мельниченко ГА, Альбекова ЖС и др. Распространенность и факторы риска развития диабетической полиневропатии у стационарных больных сахарным диабетом 1-го типа. Нервно-мышечные болезни. 2012;(1):25-31. doi:10.17650/2222-8721-2012-0-1-25-31; The DCCT Research Group. The effect of intensive diabetes therapy on the development and progression of neuropathy. Ann Intern Med. 1995 Apr 15;122(8):561-8. doi:10.7326/0003-4819-122-8-199504150-00001; Callaghan BC, Little AA, Feldman EL, et al. Enhanced glucose control for preventing and treating diabetic neuropathy. Cochrane Database Syst Rev. 2012 Jun 13;6(6):CD007543. doi:10.1002/14651858.CD007543.pub2; Brownlee M. The pathobiology of diabetic complications. A unifying mechanism. Diabetes. 2005 Jun;54(6):1615-25. doi:10.2337/diabetes.54.6.1615; Edwards JL, Vincent AM, Cheng HT, et al. Diabetic neuropathy: mechanisms to management. Pharmacol Ther. 2008 Oct;120(1):1-34. doi:10.1016/j.pharmthera.2008.05.005. Epub 2008 Jun 13.; Зотова ЕВ, Савостьянов КВ, Чистяков ДА и др. Поиск ассоциации полиморфных маркеров генов, кодирующих ферменты антиоксидантной защиты с диабетической полинейропатией у больных сахарным диабетом типа 1. Молекулярная биология. 2004;(2):244-9.; Зотова ЕВ, Чистяков ДА, Савостьянов КВ и др. Изучение ассоциации полиморфных маркеров Ala(-9) Val гена SOD2 и Arg213Gly гена SOD3 с диабетической полинейропатией у больных сахарным диабетом типа 1. Молекулярная биология. 2003;(3):345-8.; Malic RA, Tesfaye S, Thompson SD, et al. Microangiopathy in human diabetic neuropathy: relationship between capilliary abnormalities and severity of neuropathy. Diabetologia. 1993 May;36(5):454-9. doi:10.1007/BF00402283; Giannini C, Dyck PJ. Ultrastructural morphometric features in human sural nerve microvessels. J Neuropathol Exp Neurol. 1993 Jul;52(4):361-9. doi:10.1097/00005072-199307000-00003; Caneron NE, Cotter MA. Pro-inflammatory mechanisms in diabetic neuropathy: focus on the nuclear factor kappa B pathway. Curr Drug Targets. 2008 Jan;9(1):60-7. doi:10.2174/138945008783431718; Moghtaderi A, Bakhshipour A, Rashidi H. Validation of Michigan neuropathy screening instrument for diabetic peripheral neuropathy. Clin Neurol Neurosurg. 2006 Jul;108(5):477-81. doi:10.1016/j.clineuro.2005.08.003. Epub 2005 Sep 16.; Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015 Feb;14(2):162-73. doi:10.1016/S1474-4422(14)70251-0. Epub 2015 Jan 7.; Vincent AM, Callaghan BC, Smith AL, et al. Fiabetic neuropathy: cellular mechanisms as therapeutic targets. Nat Rev Neurol. 2011 Sep 13;7(10):573-83. doi:10.1038/nrneurol.2011.137; Boulton AJ, Kempler P, Ametov A, et al. Whither pathogenetic treatments for diabetic polyneuropathy? Diabetes Metab Res Rev. 2013 Jul;29(5):327-33. doi:10.1002/dmrr.2397; Строков ИА, Манухина ЕБ, Бахтина ЛЮ и др. Состояние эндогенных протекторных систем у больных инсулинзависимым сахарным диабетом с полинейропатией: эффект антиоксидантной терапии. Бюллетень экспериментальной биологии и медицины. 2000;130(10):437-41.; Borcea V, Nourooz-Zadeh J, Wolff SP, et al. Alpha-lipoic acid decreases oxidative stress in patients with diabetes mellitus. Free Radic Biol Med. 1999 Jun;26(11-12):1495-500. doi:10.1016/s0891-5849(99)00011-8; Haak ES, Usadel KH, Kohleisen M, et al. The effect of α-lipoic acid on the neurovascular reflex arc in patients with diabetic neuropathy assessed by capillary microscopy. Microvasc Res. 1999 Jul;58(1):28-34. doi:10.1006/mvre.1999.2151; Ziegler D, Hanefeld M, Ruhnau KJ, et al. Treatment of symptomatic diabetic peripheral neuropathy with the antioxidant α-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study). Diabetologia. 1995 Dec;38(12):1425-33. doi:10.1007/BF00400603; Строков ИА, Козлова НА, Мозолевский ЮВ. Эффективность внутривенного введения трометамоловой соли тиоктовой (α-липоевой) кислоты при диабетической невропатии. Журнал неврологии и психиатрии им. С.С. Корсакова. 1999;(6):18-22.; Ziegler D, Nowak H, Kempler P, et al. Treatment of symptomatic diabetic polyneuropathy with antioxidant α-lipoic acid: a meta-analysis. Diabet Med. 2004 Feb;21(2):114-21. doi:10.1111/j.1464-5491.2004.01109.x; Ruhnau KJ, Meissner HP, Finn JR, et al. Effect of 3-week oral treatment with the antioxidant thioctic acid (alpha-lipoic acid) in symptomatic diabetic polyneuropathy. Diab Med. 1999 Dec;16(12):1040-3. doi:10.1046/j.1464-5491.1999.00190.x; Ziegler D, Ametov A, Barinov A, et al. Oral treatment with α-lipoic acid improves symptomatic diabetic polyneuropathy. The SYDNEY 2 trial. Diabetes Care. 2006 Nov;29(11):2365-70. doi:10.2337/dc06-1216; Строков ИА, Фокина АС, Головачева ВА, Кочетов АГ. Эффективность тиолепты при диабетической полиневропатии (по данным исследования ЭТИКА). Журнал неврологии и психиатрии им. С.С. Корсакова. 2013;113(5):36-40.; Pop-Busui R, Boulton AJM, Feldman EL, et al. Diabetic neuropathy: A position statement by the American Diabetes Association. Diabetic Care. 2017 Jan;40(1):136-54. doi:10.2337/dc16-2042; Ziegler D, Low PA, Litchy WJ, et al. Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATAN 1 trial. Diabetes Care. 2011 Sep;34(9):2054-60. doi:10.2337/dc11-0503. Epub 2011 Jul 20.; Strokov IA, Novosadova MV, Lavrova IN, et al. The prolonged clinical effect of tioctic acid in symptomatic distal diabetic polyneuropathy. Abstr. of the 14th Annual Scientific Meeting of the DFSG and NEURODIAB, Regensburg, Germany, September 2–5 2004; 195 p.; Reljanovic M, Reichel G, Rett K, et al. Treatment of diabetic polyneuropathy with antioxidant thioctic acid (alpha-lipoic acid): a two-year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Free Rad Res. 1999 Sep;31(3):171-9. doi:10.1080/10715769900300721
-
2Academic Journal
Authors: V. V. Badokin, В. В. Бадокин
Source: Neurology, Neuropsychiatry, Psychosomatics; Vol 2, No 2 (2010); 77-82 ; Неврология, нейропсихиатрия, психосоматика; Vol 2, No 2 (2010); 77-82 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2010-2
Subject Terms: эторикоксиб, symptom-modifying therapy, nonsteroidal anti-inflammatory drugs, glucocorticoids, etoricoxib, симптом-модифицирующая терапия, глюкокортикоиды
File Description: application/pdf
Relation: https://nnp.ima-press.net/nnp/article/view/46/49; Braun J., Bollow M., Remlinger G. et al. Prevalence of spondylarthropathies in HLA- B27-positive and -negative blood donors. Arhr Rheum 1998; 41: 58-67. Ward D.D. Health related quality in ankylosing spondylitis: a survey of 175 patients. Arthr Care Res 1999; 12: 247-55. Gran О.Т., Skomvoll J.F. The outcome of ankilosing spondylitis: a study of 100 patients. Br J Rheumatol 1997; 36(7): 766-71. McGonagle D., Khan M.A., Mazzo-Ortega H. et al. Enthesitis in spondyloarthritis. Curr Opin Rheumatol 1999; 11(4): 244-50. Dougados M., Dijrmans B., Khan M. et al. Сonventional treatments for ankylosing spondylitis. Ann Rheum Dis 2002; 61(Suppl. III): 40-50. Алексеев В.В. Диагностика и лечение болей в спине. Соnsilium medicum 2002; 4(2): 96-102. Chen D.-F., Bianchetti M., Weisendanger M. Motor disturbances. R Benecke et al. (eds). L., 1987. Amor B. Data management in spondylarthropathies. Rheumatol Eur 1996; 25(3): 92-5. Wanders A., Heijde D., Landewе R. et al. Non-steroidal anti-inflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthr Rheum 2005; 52(6): 1756-65. Dougados M., Revel M., Khan M. Spondyloarthropathy treatment: progress in medical treatment, physical therapy and rehabilitation. Baillaries Clin Rheumatol 1998; 12: 717-36. Friesen R.W., Brideau C., Chan C.C. et al. 2-Pyridinyl-3-(4-methylsulfonyl)phenylpyridines: selective and orally active cyclooxygenase-2 inhibitors. Bioorg Med Chem Lett 1998; 8(19): 2777-82. Инструкция по медицинскому применению препарата Аркоксиа (эторикоксиб), 2008. http://www.vidal.ru/poisk_preparatov/arcox-ia.htm. Greenwald M., Peloso P., Hasler F. et al. Etoricoxib improves pain and function in rheumatoid arthritis patients on background biologic therapy. Arthr Rheum 2009; 60(10, Suppl.): 606-13 Van der Heijde D., Baraf H.S., Ramos-Remus C. et al. Evalution of the efficacy of etorycoxib in ankylosing spondylitis. Results of a fifty-two-week, randomized, controlled study. Arthr Rheum 2005; 52: 1205-16. Hunt R.H., Harper S., Watson D.J. et al. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events. Am J Gastroenterol 2003; 98: 725-33. Ramey D.R., Watson D.J., Yu C. et al. The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib versus. nonselective NSAIDs: an updated combined analysis. Curr Med Res Opin 2005; 21: 715-22. Watson D.J., Bolognese J.A., Yu C. et al. Use of gastroprotective agents and discontinuations due to dyspepsia with the selective cyclooxygenase-2 inhibitor etoricoxib compared with non-selective NSAIDs. Curr Med Res Opin 2004; 20: 1899-908.
-
3Academic Journal
Authors: Бадокин, Владимир
Subject Terms: АНКИЛОЗИРУЮЩИЙ СПОНДИЛОАРТРИТ, СИМПТОМ-МОДИФИЦИРУЮЩАЯ ТЕРАПИЯ, ГЛЮКОКОРТИКОИДЫ, ЭТОРИКОКСИБ
File Description: text/html
-
4Academic Journal
Source: Неврология, нейропсихиатрия, психосоматика.
Subject Terms: АНКИЛОЗИРУЮЩИЙ СПОНДИЛОАРТРИТ, СИМПТОМ-МОДИФИЦИРУЮЩАЯ ТЕРАПИЯ, ГЛЮКОКОРТИКОИДЫ, ЭТОРИКОКСИБ, 3. Good health
File Description: text/html
